Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
2001
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
D11AH02
|
| gptkbp:CASNumber |
137071-32-0
|
| gptkbp:chemicalFormula |
C43H68N2O11
|
| gptkbp:contraindication |
immunocompromised patients
|
| gptkbp:drugClass |
gptkb:immunotherapy
|
| gptkbp:form |
gptkb:butter
|
| gptkbp:genericName |
gptkb:pimecrolimus
|
| gptkbp:legalStatus |
Rx-only
|
| gptkbp:manufacturer |
gptkb:Novartis
|
| gptkbp:mechanismOfAction |
gptkb:immunosuppressant
|
| gptkbp:notRecommendedFor |
children under 2 years
|
| gptkbp:powers |
1%
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:prescriptionStatus |
prescription only
|
| gptkbp:riskFactor |
possible increased risk of skin cancer
|
| gptkbp:routeOfAdministration |
topical
|
| gptkbp:sideEffect |
burning sensation
redness irritation |
| gptkbp:storage |
store at room temperature
|
| gptkbp:usedFor |
gptkb:eczema
gptkb:atopic_dermatitis |
| gptkbp:bfsParent |
gptkb:Valeant_Pharmaceuticals
|
| gptkbp:bfsLayer |
6
|
| https://www.w3.org/2000/01/rdf-schema#label |
Elidel
|